Trials / Unknown
UnknownNCT05107596
Evaluation of CCR2 in Patients Post Myocardial Infarction
Preliminary Evaluation of 64Cu-DOTA-ECL1i in Patients Post-ST-Elevation Myocardial Infarction(STEMI)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 21 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
To determine the feasibility of 64Cu-DOTA-ECL1i, an investigational PET imaging drug, at the cellular level in the myocardium for individuals who have suffered a heart attack or who have other inflammatory heart disease.
Detailed description
To determine the feasibility of 64Cu-DOTA-ECL1i to detect CCR2+monocytes and macrophages which are cells that are responsible for protecting tissues from foreign substances in the myocardium by PET/MR and PET/CT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 64Cu-DOTA-ECL1i | Inject PET Radioisotope for imaging |
Timeline
- Start date
- 2018-11-24
- Primary completion
- 2025-11-24
- Completion
- 2025-11-24
- First posted
- 2021-11-04
- Last updated
- 2022-11-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05107596. Inclusion in this directory is not an endorsement.